心力衰竭猝死的防治
吴永全 吴永全，上海同济大学附属同济医院心内科，200065
摘要: 心力衰竭(简称心衰)是一种终末期心脏疾病。随着年龄增高及心肌梗死(简称心梗)等其他心脏疾病的成功救治，心衰的患病率显著上升，据调查我国心衰患病率为0.9% [1] 。心衰是心脏性猝死(SCD)的常见病因。SCD机制复杂，但大部分由室性心动过速(简称室速)、心室颤动(简称室颤)等恶性心律失常引起。因此，预防恶性心律失常的发生，及时终止室速或室颤是防治SCD发生的关键环节。 一、抗心律失常药物在心脏性猝死防治中的作用..
HTML
PDF文献标引:吴永全.心力衰竭猝死的防治.中华临床医师杂志（电子版）,2007,1(4):229-231.
参考文献
[1] 顾东风，黄广勇，何江，等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志，2003,31(1)：3－6.[2] CIBIS-Ⅱ investigators and Committee.The cardiac insufficiency bisoprolol study Ⅱ (CIBICⅡ)：a randomized trial.Lancet,1999,353(9146)：9－13.[PubMed]
[3] McMurray J，Kober L，Robertson M，et al.Antiarrhythmic effect of carvedilol after acute myocardial infarction：Results of the carvedilol post-infarct survival control in left ventricular dysfunction(CAPRICORN) trial.J Am Coll Cardio1,2005,45(4)：525－530.[PubMed]
[4] Doval HC，Nul DR，Grancelli HO，et al.Randomised trial of low-dose amiodarone in severe congestive heart failure.Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA).Lancet,1994,344 (8921)：493－498.[PubMed]
[5] Singh SN，Fletcher RD，Fisher SG，et al.For the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure：Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia.N Engl J Med,1995,333(2)：77－82.[PubMed]
[6] Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure：meta-analysis of individual data from 6500 patients in randomised trials.Amiodarone Trials Meta-Analysis Investigators.Lancet,1997,350(9089)：1417－1424.[PubMed]
[7] Vyas AK，Gun H，Moss AJ，et al.Reduction in ventricular tachyarrhythmias with statins in the multicenter automatic defibrillator implantation trial(MADIT)-Ⅱ.J Am Coll Cardio1,2006,47(4)：769－773.[PubMed]
[8] Al-Mallah MH，Tleyjeh IM，Abdel-Latif AA，et al.Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function：A systematic review and meta-analysis of randomized controlled trials.J Am Coll Cardiol,2006,47(8)：1576－1583.[PubMed]
[9] Teo KK，Mitchell LB，Pogue J，et al.Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.Circulation,2004,110(11)：1413－1417.[PubMed]
[10] Solomon SD，Wang D，Finn P，et al.Effect of candesartan on cause specific mortality in heart failure patients：The candesartan in heart failure assessment of reduction in mortality and morbidity(CHARM) program.Circulation,2004,110 (15)：2180－2183.[PubMed]
[11] Pitt B，Remme W，Zannad F，et al.Eplerenone，a selective aldosterone blocker，in patients with left ventricular dysfunction after myocardial infarction.N Engl J Med,2003,348(14)：1309－1321.[PubMed]
[12] Moss AJ，Hall WJ，Cannom DS，et al.Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular ar rhythmias.N Engl J Med,1996,335(26)：1933－1940.[PubMed]
[13] Buxton AE，Lee KL，Fischer JD，et al.A randomized study of the prevention of sudden death in patients with coronary artery disease.Multicenter Unsustained Tachycardia Trial Investigators.N Engl J Med,1999,341(25)：1882－1890.[PubMed]
[14] Moss AJ，Zareba W，Hall WJ，et al.Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.N Engl J Med,2002,346(12)：877－883.[PubMed]
[15] Kadish A，Dyer A，Daubert JP，et al.Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.N Engl J Med,2004,350(21)：2151－2158.[PubMed]
[16] Hohnloser SH，Kuck KH，Dorian P，et al.Randomized trial of prophylactic im plantable cardioverter defibrillator after acute myocardial infarction.N Engl J Med,2004,351(24)：2481－2488.[PubMed]
[17] Bardy GH，Lee KL，Mark DB，et al.For the Sudden Cardiac Death in Heart Failure Trial(SCD-HeFT)Investigators.Amiodaroneoran implantable cardioverter-defibrillator for congestive heart failure.N Engl J Med,2005,352(3)：225－237.[PubMed]
[18] A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.N Engl J Med,1997,337(22)：1576－1583.[PubMed]
[19] Connolly SJ，Gent M，Roberts RS，et al.Canadian Implantable Defibrillator Study( CIDS)：a randomized trial of the implantable cardioverter defibrillator against amiodarone.Circulation,2000,101(11)：1297－1302.[PubMed]
[20] Siebels J，Cappato R，Ruppel R，et al.Preliminary results of the Cardiac Arrest Study Hamburg(CASH).CASH Investigators.Am J Cardio1,1993,72(16)：109F－113F.[PubMed]
[21] Lozano I， Bocchiardo M， Achtelik M， et al.VENTAK CHF/CONTAK CD Investigators Study Group.Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias.Pacing Clin Electrophysiol,2000,23(11 Pt 2)：1711－1712.[PubMed]
[22] Bristow MR，Saxon LA，Boehmer J，et al.Comparison of Medical Therapy，Pacing，and Defibrillation in Heart Failure(COMPANION) Investigators.Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.N Engl J Med,2004,350 (21)：2140－2150.[PubMed]
[23] Young JB，Abraham WT，Smith AL，et al.Multicenter InSync ICD Randomized Clinical Evaluation( MIRACLE ICD) Trial Investigators.Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure：the MIRACLE ICD trial.JAMA,2003,289(20)：2685－2694.[PubMed]
[24] Cleland J，Daubert JC，Erdmann E，et al.The effect of cardiac resynchronization on morbidity and mortality in heart failure.N Engl J Med,2005,352(15)：1539－1549.[PubMed]
